Paternal valproate exposure shows no increased risk of neurodevelopmental disorders in children, indicating safety.
Paternal use of valproate within the 90 days before conception was not associated with an increased risk of NDDs in offspring after adjustment for confounding in Norwegian and Taiwanese cohorts. (Funded by the Research Council of Norway and the National Science and Technology Council of Taiwan.).
No takes yet. Share an insight, caveat, or question.
Meng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: